LPTX vs. MNMD, STOK, ARCT, RNAC, VERV, MLYS, MGTX, SAGE, PHAT, and ESPR
Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Mind Medicine (MindMed) (MNMD), Stoke Therapeutics (STOK), Arcturus Therapeutics (ARCT), Cartesian Therapeutics (RNAC), Verve Therapeutics (VERV), Mineralys Therapeutics (MLYS), MeiraGTx (MGTX), Sage Therapeutics (SAGE), Phathom Pharmaceuticals (PHAT), and Esperion Therapeutics (ESPR). These companies are all part of the "pharmaceutical products" industry.
Leap Therapeutics vs.
Mind Medicine (MindMed) (NASDAQ:MNMD) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 2.3% of Mind Medicine (MindMed) shares are owned by company insiders. Comparatively, 5.4% of Leap Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Mind Medicine (MindMed) has a beta of 2.6, meaning that its share price is 160% more volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.
Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mind Medicine (MindMed)'s return on equity of -47.56% beat Leap Therapeutics' return on equity.
Leap Therapeutics received 243 more outperform votes than Mind Medicine (MindMed) when rated by MarketBeat users. However, 92.73% of users gave Mind Medicine (MindMed) an outperform vote while only 69.01% of users gave Leap Therapeutics an outperform vote.
In the previous week, Leap Therapeutics had 1 more articles in the media than Mind Medicine (MindMed). MarketBeat recorded 3 mentions for Leap Therapeutics and 2 mentions for Mind Medicine (MindMed). Leap Therapeutics' average media sentiment score of 0.61 beat Mind Medicine (MindMed)'s score of 0.49 indicating that Leap Therapeutics is being referred to more favorably in the news media.
Mind Medicine (MindMed) currently has a consensus target price of $26.75, suggesting a potential upside of 273.60%. Leap Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 194.12%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, equities research analysts plainly believe Mind Medicine (MindMed) is more favorable than Leap Therapeutics.
Summary
Mind Medicine (MindMed) and Leap Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Leap Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Leap Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LPTX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free LPTX Stock Alerts